Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor

NCT04869943 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT04869943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Lead sponsor
Veru Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 12, 2021
Completion date
January 9, 2024
Enrollment
52 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer